Shield Therapeutics Achieves Positive Cash Flow in Q4 2025 and Forecasts Operating Profit for 2026

Encouragingly, consignment-based prescriptions – dispensed at a subsidised price and not reimbursed by payors – were c. 21% of dispenses in Q4 (c. 22% in Q4 2024). A lower reliance on consignment should support cash conversion as more volume moves into fully reimbursed channels.

Cash and balance sheet: positive operating cash flow and $11.6m cash

Cash and cash equivalents stood at $11.6m at 31 December 2025, up from $8.6m at 30 September 2025. Shield achieved positive operating cash flow of $1m in Q4, excluding $1.96m of net proceeds from an amended Senior Secured Debt Financing received in the quarter.

That operating cash flow inflection is important. As the CEO put it, reaching cash flow positivity is a milestone that supports growth without the need for further external financing. The company’s wider cash runway is not disclosed, but the combination of rising revenues, improving mix and positive operating cash flow is moving Shield in the right direction.

Outlook: operating profit expected in 2026

Shield states that it expects to deliver an operating profit in 2026. That would mark a key transition from cash burn to cash generation, driven by scaling ACCRUFeR in the US and disciplined cost and working capital management.

For valuation, shifting into operating profitability can be a catalyst – it reduces uncertainty around future funding and can broaden the investor base. Execution remains crucial, particularly sustaining script growth while protecting net pricing.

What it means for investors: positives and watch items

• Momentum intact – FY25 Group revenues of c. $50m and ACCRUFeR revenues up 56% to $46m show strong commercial traction.

• Unit economics improving – FY25 ANSP up 21% to $223 and total scripts up c. 33% underpin operating leverage.

• Cash conversion turning – positive Q4 operating cash flow and cash of $11.6m at year-end improve financial flexibility.

• Guidance signal – management expects an operating profit in 2026, a meaningful step change.

• Pricing mix to watch – Q4 ANSP of $222 was lower year-on-year due to more rebated coverage. Monitor net price in 2026.

• Consignment mix still present – c. 21% of Q4 dispenses were consignment-based. Further reductions would support margins and cash.

• Granularity – detailed FY25 P&L, cash burn by quarter, and 2026 guidance beyond operating profit are not disclosed.

ACCRUFeR and the market opportunity

ACCRUFeR/FeRACCRU (ferric maltol) is a novel, non-salt-based oral iron therapy for adults with iron deficiency, with or without anaemia. It is the first and only FDA-approved oral iron to treat ID/IDA, and has shown efficacy and good tolerability across multiple clinical trials.

Shield cites a US patient population of about 20 million and a $2.3 billion market opportunity for ID and IDA. ACCRUFeR is described as the leading #1 branded prescription oral iron in the market today for ID/IDA (data source – IQVIA Xponent PlanTrak).

Key catalyst: investor presentation

Management will host a live online presentation at 2:00 pm (GMT) on 22 January 2026 via the Investor Meet Company platform. You can register here:

Investor Meet Company – Shield Therapeutics

Bottom line: scaling up with a line of sight to profitability

Shield’s FY25 finish was solid: record quarterly dispenses, rising annual price and volume, and operating cash flow turning positive. The guidance for operating profit in 2026 raises the stakes for execution, but the commercial and financial trends are supportive.

If management can keep scripts growing while managing rebate pressure, and continue to lower the consignment mix, the step to sustainable profitability looks achievable. For now, this is a constructive update that should build confidence going into 2026.